updat post call still tough cost
industri headwind continu least
earlier today publish first look result link
addit takeaway confer call overal miss guid
compound-annual-growth-rate surpris given recent industri headwind higher
patient concess built guid headwind vitamin
d/hcv/drug monitor improv signific denial
annual lap still drag due tighter polici around
test despit higher averag test price hospit lab consid
in-network long hospit in-network therefor hospit insourc
issu may ultim benefit design flaw littl control
price headwind frame total compar
price cut given analyst day although spell specif
indirect pama influenc lh link
invigor initi help off-set margin hit
plu side track least increment sale growth
 potenti addit acquisit could boost
outlook indic first tranch anticip share gain
happen quickli signific part volum build span
also await unh decis prefer lab network plan may help clarifi
competit dynam nation hospital/region lab take
time share gain price dynam industri consolid theme play
dgx invigor program help mitig near-term margin headwind
magnitud cost save endeavor key variabl model
adjust estim sale ep modestli
model sale adj ep estimate
save op lower sale margin assumpt trim po
still base ev/ebitda estimate although believ
nation lab eventu benefit on-going lab industri turmoil
remain cautiou given limit visibl reiter under-perform rate
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
largest provid clinic diagnost
test relat servic deliv
nation network full-servic clinic
laboratori patient servic center
clinic lab oper highli competit
price-deflationari environ although
long-term see upsid potenti
elev lab consolid catalyz medicar
opportun monet lab data recent
multipl guidanc cut suggest visibl
limit see potenti
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
price object base ev/ebitda multipl line
compani median two year forward multipl last ten year given
recent soft volum trend lack full understand root caus
weak believ still potenti downsid risk addit multipl
upsid risk faster expect materi hospit lab consolid
trend margin expans due higher specialti test mix faster volum growth
consum genom trend
downsid risk greater expect price headwind lower expect test
volum growth competit execut risk integr risk data privaci risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
